11/13/2025

How a ‘One and done’ Gene-editing Treatment Could Lower Cholesterol

The results of an early trial show a promising development

In a cutting-edge medical experiment, a small group of people who had high cholesterol despite taking conventional drugs to lower it saw significant reductions in two major risk factors for heart disease after receiving a single gene-editing treatment at the highest dose.

The study, funded by CRISPR Therapeutics, is an early-stage clinical trial with just 15 participants, but it represents a step forward in a bold quest to treat common diseases with a one-time treatment that tweaks people’s genes.

A host of powerful tools, propelled by the discovery of CRISPR gene editing, which won the Nobel Prize for chemistry in 2020, has sparked the dream of “one and done” treatments for a host of ailments.

Please select this link to read the complete article from The Washington Post.